Biography and Research Information
OverviewAI-generated summary
Gunaganti Naresh's research focuses on the discovery and chemical optimization of novel therapeutic agents. His work has involved the development of compounds targeting specific molecular pathways implicated in disease. He has investigated potential treatments for Human African Trypanosomiasis and explored inhibitors for FLT3-ITD, including those resistant to existing therapies. His publications also detail the discovery of orally active selective aurora kinase B inhibitors.
Naresh collaborates with researchers at the University of Arkansas for Medical Sciences, including Xiuqi Wang and Phuc Tran. His scholarship metrics include an h-index of 13, with 30 total publications and 563 citations. He is actively publishing, with his most recent work in 2025.
Metrics
- h-index: 13
- Publications: 30
- Citations: 571
Selected Publications
-
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor (2025)
-
An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L (2023)
Collaboration Network
Top Collaborators
Xiuqi Wang
University of Arkansas for Medical Sciences
2 shared publications
In database
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Phuc Tran
University of Arkansas for Medical Sciences
2 shared publications
In database
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Hongyu Li
The University of Texas Health Science Center at San Antonio (US)
2 shared publications
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Baljinder Singh
Northeastern University (US)
1 shared publication
- Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
Amrita Sharma
Kennesaw State University (US)
1 shared publication
- Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
Mitch Rivers
Northeastern University (US)
1 shared publication
- Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
Pradip K. Gadekar
Northeastern University (US)
1 shared publication
- Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
Brady Greene
Northeastern University (US)
1 shared publication
- Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
Michael Chichioco
Northeastern University (US)
1 shared publication
- Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
Carlos E. Sanz-Rodríguez
University of Georgia (US)
1 shared publication
- Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
Courtney Fu
Northeastern University (US)
1 shared publication
- Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
Catherine Leblanc
Northeastern University (US)
1 shared publication
- Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
Erin Burchfield
Northeastern University (US)
1 shared publication
- Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
Nyle Sharif
Northeastern University (US)
1 shared publication
- Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
Benjamin U. Hoffman
University of Georgia (US)
1 shared publication
- Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
Similar Researchers
Based on overlapping research topics
Anupreet Kharbanda
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Protein Kinase Inhibitors
Alicja Urbaniak
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Drug Delivery Systems
Brendan Frett
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Protein Kinase Inhibitors
Disease Mechanisms Research
Fengping Lv
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications
Baha’a Jabali
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications
Peter A. Crooks
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Drug Delivery Systems